⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Official Title: A Multi-center, Open-label, Single-arm Phase I Dose-escalation and Phase II Dose-expansion Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Study ID: NCT04954001

Interventions

FCN-159

Study Description

Brief Summary: FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib. FCN-159 is an orally available and highly potent selective inhibitor of MEK1/2, which is expected to be a targeted therapy for the treatment of advanced solid tumors and neurofibromatosis type 1.

Detailed Description:

Keywords

Eligibility

Minimum Age: 2 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Children's Hospital Los Angeles, Los Angeles, California, United States

Principal Investigator Hans, Gainesville, Florida, United States

John Hopkins All Children Hospital, Saint Petersburg, Florida, United States

Henry Ford Health System, Detroit, Michigan, United States

Medical University of South Carolina - Hollings Cancer Center - PPDS, Charleston, South Carolina, United States

Research Site, Beijing, , China

Research Site, Guangzhou, , China

Research Site, Hangzhou, , China

Research Site, Shanghai, , China

Research Site, Shijiazhuang, , China

Research Site, Wuhan, , China

Hospital Universitario Vall d'Hebron, Barcelona, , Spain

Hospital Universitario 12 de Octubre, Madrid, , Spain

Hospital Universitario La Paz, Madrid, , Spain

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: